Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing and sequence of vaccination against COVID-19 and Influenza
2021-002186-17Phase 4Completed
- Sponsor
- Radboudumc
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of tozinameran, elasomeran and Influenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen in coronavirus disease 2019 (COVID-19) and influenza (2 arms), sponsored by Radboudumc. Primary endpoint: Geometric mean concentrations of RBD- and spike-specific IgG and IgA. Started Apr 2021; status: completed.
02
Drugs
tozinameranelasomeranInfluenza A virus A/Texas/50/2012 X-223A (H3N2) hemagglutinin antigen
03
Conditions
coronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on 2021-002186-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002186-17.